Xenetic Biosciences Inc (XBIO) - Total Liabilities
Based on the latest financial reports, Xenetic Biosciences Inc (XBIO) has total liabilities worth $1.11 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check XBIO asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Xenetic Biosciences Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Xenetic Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see XBIO asset base.
Xenetic Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Xenetic Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suvidhaa Infoserve Limited
NSE:SUVIDHAA
|
India | Rs355.20 Million |
|
Austchina Holdings Ltd
AU:AUH
|
Australia | AU$1.64 Million |
|
Organoclick AB
ST:ORGC
|
Sweden | Skr121.59 Million |
|
Cann Group Ltd
AU:CAN
|
Australia | AU$21.39 Million |
|
ESE Entertainment Inc
V:ESE
|
Canada | CA$9.18 Million |
|
Sentage Holdings Inc
NASDAQ:SNTG
|
USA | $2.00 Million |
|
Elecster Oyj A
HE:ELEAV
|
Finland | €17.36 Million |
|
Australasian Metals Ltd
AU:A8G
|
Australia | AU$210.16K |
Liability Composition Analysis (2011–2024)
This chart breaks down Xenetic Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See XBIO equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xenetic Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xenetic Biosciences Inc (2011–2024)
The table below shows the annual total liabilities of Xenetic Biosciences Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $894.26K | +10.46% |
| 2023-12-31 | $809.59K | -24.56% |
| 2022-12-31 | $1.07 Million | -24.48% |
| 2021-12-31 | $1.42 Million | +47.42% |
| 2020-12-31 | $963.97K | -77.76% |
| 2019-12-31 | $4.33 Million | -4.09% |
| 2018-12-31 | $4.52 Million | -7.07% |
| 2017-12-31 | $4.86 Million | +1.20% |
| 2016-12-31 | $4.80 Million | -53.35% |
| 2015-12-31 | $10.30 Million | +76.50% |
| 2014-12-31 | $5.84 Million | -14.79% |
| 2013-12-31 | $6.85 Million | +49.11% |
| 2012-12-31 | $4.59 Million | +1980.58% |
| 2011-12-31 | $220.74K | -- |
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, a… Read more